Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Announce Earnings of -$1.19 Per Share

Equities research analysts predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will post earnings per share of ($1.19) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.30) and the highest estimate coming in at ($1.13). Global Blood Therapeutics posted earnings of ($0.93) per share in the same quarter last year, which indicates a negative year over year growth rate of 28%. The business is expected to report its next quarterly earnings results on Wednesday, February 26th.

On average, analysts expect that Global Blood Therapeutics will report full year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.27) to ($4.09). For the next year, analysts expect that the firm will report earnings of ($4.61) per share, with EPS estimates ranging from ($5.57) to ($4.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the business posted ($0.83) EPS.

Several research firms recently issued reports on GBT. Wedbush restated a “buy” rating and issued a $143.00 price target on shares of Global Blood Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald reissued a “buy” rating and set a $98.00 target price (down previously from $110.00) on shares of Global Blood Therapeutics in a report on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday, October 9th. Morgan Stanley set a $60.00 price target on shares of Global Blood Therapeutics and gave the company a “hold” rating in a research note on Friday, August 9th. Finally, Nomura raised their price target on shares of Global Blood Therapeutics from $109.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $91.44.

Shares of Global Blood Therapeutics stock traded up $0.44 on Wednesday, hitting $72.93. The stock had a trading volume of 68,652 shares, compared to its average volume of 1,331,700. The stock has a market cap of $4.01 billion, a price-to-earnings ratio of -21.39 and a beta of 1.70. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.04. Global Blood Therapeutics has a twelve month low of $34.92 and a twelve month high of $73.23. The business’s 50 day moving average is $53.03 and its two-hundred day moving average is $53.44.

In other Global Blood Therapeutics news, insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $54.36, for a total transaction of $150,305.40. Following the completion of the transaction, the insider now directly owns 887 shares in the company, valued at $48,217.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Tricia Borga Suvari sold 3,434 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $66.74, for a total value of $229,185.16. Following the transaction, the insider now directly owns 6,752 shares of the company’s stock, valued at approximately $450,628.48. The disclosure for this sale can be found here. Insiders have sold 36,616 shares of company stock worth $2,096,540 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in GBT. Quest Capital Management Inc. ADV acquired a new position in Global Blood Therapeutics during the third quarter worth about $26,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $27,000. Lindbrook Capital LLC boosted its stake in shares of Global Blood Therapeutics by 133.3% in the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after purchasing an additional 400 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of Global Blood Therapeutics in the 2nd quarter valued at approximately $42,000. Finally, Truvestments Capital LLC grew its holdings in shares of Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock valued at $45,000 after purchasing an additional 300 shares during the last quarter. 98.78% of the stock is currently owned by institutional investors and hedge funds.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: What is the Russell 2000 Index?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.